Equity Details
Price & Market Data
Price: $9.10
Daily Change: -$0.18 / 1.98%
Daily Range: $8.96 - $9.35
Market Cap: $2,005,676,800
Daily Volume: 3,703,193
Performance Metrics
1 Week: -5.66%
1 Month: 3.39%
3 Months: 1.44%
6 Months: -15.58%
1 Year: 23.95%
YTD: -24.55%
About Ocular Therapeutix, Inc. (OCUL)
Get the full story on Ocular Therapeutix, Inc. (OCUL). Price: 9.10, daily change: -$0.18 / 1.98%. Market cap: 2,005,676,800. Performance from YTD to 1-year is available.
Company Details
Employees: 325
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.